|
With ten years of experience in drug discovery and then business development in the pharmaceutical industry, Dr. Berniac co-founded Akrivis Technologies LLC, a life sciences startup company headquartered in Massachusetts. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases from the applications of its patented ZEPTACSYS(TM) technology platform. Prior to that, Joel became in 2008 Associate Director of Business Development at Paratek Pharmaceuticals, Inc. in Boston where he overviewed the preclinical research portfolio and out-licensing activities for rheumatoid arthritis. In 2005, Joel earned an M.B.A. from Northeastern University while rising to the position of Principal Scientist at Paratek where he had been involved since 2001 in the discovery of preclinical drug candidates for a variety of therapeutic areas such as antibacterial, malaria, multiple sclerosis and spinal muscular atrophy, a neurological genetic disease. Indeed, Joel started his career as a medicinal chemist in 1999 at Bayer Pharmaceuticals in Connecticut, where he was involved in the design and synthesis of preclinical drug candidates in the CNS (obesity) and diabetes therapeutic areas. Joel earned his Ph.D. in Organic Chemistry in 1999 from the University of Notre Dame in South Bend, Indiana, after graduating from the French Engineering School ESCIL-CPE Lyon in France. [back] |
Entrepreneurs américains “mentors”: Joel BERNIAC
